Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript

SA Transcripts158.75K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD March 2, 2026 7:30 AM EST Company Participants William Slattery - Vice President of Investor RelationsPravin Dugel - Executive Chairman, President & CEOPeter Kaiser - Chief Development OfficerJeffrey Heier, - Chief Scientific Officer Conference Call Participants Arshad Khanani - Sierra Eye AssociatesDarius M. MoshfeghiTazeen Ahmad - BofA Securities, Research DivisionBiren Amin - Piper Sandler & Co., Research DivisionColleen Hanley - Robert W. Baird & Co. Incorporated, Research DivisionSean McCutcheon - Raymond James & Associates, Inc., Research DivisionLisa Walter - RBC Capital Markets, Research DivisionYuxi Dong - Jefferies LLC, Research DivisionJonathan Wolleben - Citizens JMP Securities, LLC, Research DivisionYi Chen - H.C. Wainwright & Co, LLC, Research DivisionLachlan Hanbury-Brown - William Blair & Company L.L.C., Research DivisionSerge Belanger - Needham & Company, LLC, Research DivisionWilliam Maughan - Clear Street LLC., Research Division Presentation Operator Good morning, and welcome to the Ocular Therapeutix SOL-1 Data Review Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for replay on the Investor Relations section of the Ocular Therapeutix website. I would now like to turn the call over to Ocular's Vice President of Investor Relations, Bill Slattery, Jr. Please go ahead, Mr. Slattery. William SlatteryVice President of Investor Relations Good morning, everyone, and thank you for joining us today. This past Friday, February 27, 2026, we presented detailed results from the SOL -1 Phase III clinical trial of AXPAXLI, also referred to as OTX-TKI in wet AMD at the 49th Macula Society Annual Meeting. We refer everyone to the Macula Society presentation slides and video recording for a comprehensive update of the clinical data released. The presentation is available on the Events and Presentations section of our Investor Relations website.